香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分 內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 碧生源控股有限公司 BESUNYEN HOLDINGS COMPANY LIMITED ( 於開曼群島註冊成立的有限公司 ) (股份代號：926) 於二零二五年八月二十五日舉行的 股東特別大會投票表決結果 碧生源控股有限公司(「本公司」)董事(「董事」)會(「董事會」)欣然宣佈，在本公 司於二零二五年八月二十五日舉行的股東特別大會(「股東特別大會」)上，載列於日 期為二零二五年八月八日的股東特別大會通告(「該通告」)內的建議決議案(「該決議 案」)，已由本公司股東以投票表決方式正式通過。有關該決議案的投票表決結果如 下： | 普通決議案 | 票數 | | | --- | --- | --- | | | (概約%) | | | | 贊成 | 反對 | | 誠如通告決議案所載，批准自本公司股份溢價賬中 | 62,708,199 | 0 | | 宣派及派發中期股息每股普通股0.15港元，以及其 | (100. ...

Dear Non-registered Holder(s) (Note) , BESUNYEN HOLDINGS COMPANY LIMITED (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） (Stock code 股份代號: 926) Besunyen Holdings Company Limited (the "Company") - Extraordinary General Meeting ("EGM") of the Company to be held on Monday, 25 August 2025 The EGM of the Company will be held virtually using online platform at http://meetings.computershare.com/Besunyen_EGM202508 (the "Online Platform") at 10:30 a.m. on Monday, 25 August 2025. Sharehol ...

You will be able to view the live video broadcast of the EGM, cast your votes on the resolutions in real time and submit questions to the Company. From 10:00 a.m. on Monday, 25 August 2025, you can log in to the Online Platform for the EGM by visiting the meeting website and entering the following details: BESUNYEN HOLDINGS COMPANY LIMITED (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） (Stock code 股份代號: 926) Dear Shareholder(s), 8 August 2025 Besunyen Holdings Company Limited ( ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本通告全部或任何 部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 BESUNYEN HOLDINGS COMPANY LIMITED 碧生源控股有限公司 （於開曼群島註冊成立的有限公司） 茲通告碧生源控股有限公司（「本公司」）謹訂於二零二五年八月二十五日（星期一）上 午十時三十分以電子方式舉行股東特別大會（「股東特別大會」），以進行下列事宜： 普通決議案 「動議謹此批准自本公司的股份溢價賬中宣派及派發中期股息每股普通股0.15港元 （「中期股息」），並謹此授權本公司任何一名董事（或如須加蓋公司印鑑，則授權本 公司任何兩名董事）按其全權酌情認為就上述各項而言屬必需、適宜、合適及權宜 者採取行動、進行事宜並簽立文件及契據。」 承董事會命 碧生源控股有限公司 （股份代號：926） 股東特別大會通告 – 1 – 附註： 1. 股 東 特 別 大 會 將 以 電 子 方 式 舉 行 。 登 記 股 東 將 可 到 訪 網 站 http://meetings.computersh ...

將於二零二五年八月二十五日（星期一）舉行之股東特別大會 （或其任何續會）之代表委任表格 碧生源控股有限公司 BESUNYEN HOLDINGS COMPANY LIMITED （於開曼群島註冊成立的有限公司） （股份代號：926） 日期 簽署 股本中每股面值0.0003333332美元股份（「股份」） 股 之登記持有人，茲委任本公司股東特別大會（「大會」）主席 （附註3） 或 地址為 （電郵地址） 擔任本人╱吾等受委代表，為及代表本人╱吾等出席本公司謹訂於二零二五年八月二十五日（星期一）上午十時 三十分以電子形式舉行之大會（或其任何續會），藉以考慮並酌情通過召開大會通告（「通告」）所載之決議案，並 在大會（或其任何續會）代表本人╱吾等按照以下指示以本人╱吾等名義就有關決議案投票 （附註4） ： | 誠如通告決議案所載，批准自本公司股份溢價賬中宣派及派發中期股 | | | | | | --- | --- | --- | --- | --- | | 普通決議案 息每股普通股0.15港元，以及其附帶的所有事宜。 | 贊成 | （附註4） | 反對 | （附註4） | 本人╱吾等 （附註1） 地址為 為碧生源控股有限 ...

BESUNYEN HOLDINGS COMPANY LIMITED 碧生源控股有限公司 閣下如已將名下的碧生源控股有限公司股份全部出售或轉讓，應立即將本通函連同隨附的 代表委任表格送交買主或承讓人，或經手出售或轉讓的銀行經理、持牌證券交易商或其他代 理商，以便轉交買主或承讓人。 閣下對本通函的任何內容或應採取的行動如有任何疑問，應諮詢 閣下的持牌證券交易商或 其他註冊證券機構、銀行經理、律師、專業會計師或其他專業顧問。 （於開曼群島註冊成立的有限公司） （股份代號：926） 此 乃 要 件 請 即 處 理 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示概不就因本通函全部或任何部分內容而產生 或因倚賴該等內容而引致的任何損失承擔任何責任。 建議宣派及派發中期股息 及 股東特別大會通告 碧生源控股有限公司謹訂於二零二五年八月二十五日（星期一）上午十時三十分以電子方式 舉行股東特別大會，召開股東特別大會的通告載於本通函第7至9頁。 無論 閣下能否出席股東特別大會，務請按隨附的代表委任表格印列的指示填妥表格，盡快 但無論如何於股東特別大會或其任 ...

Core Viewpoint - Biyuan's performance in the first half of 2025 shows steady progress, with revenue reaching 258.9 million RMB, a year-on-year increase of 1.8% [1]. Financial Performance - Total comprehensive income reached 12.4 million RMB, up 45.9% from 8.5 million RMB in the same period last year [1]. - The company's profitability is recovering, with a net profit attributable to shareholders of 14.8 million RMB in 2024, compared to a loss of 299 million RMB in 2023 [3]. - Gross margin improved significantly from 46.91% in 2023 to 67.28% in 2024, indicating effective product structure optimization and cost control measures [3]. Product Performance - The traditional "Four Teas" business generated revenue of 129.1 million RMB, a decline of 4.7% year-on-year, reflecting increased competition and changing consumer demand in the health tea market [4]. - The weight loss drug segment saw revenue of 94.4 million RMB, a growth of 15.0%, primarily due to the ongoing promotion of the Orlistat product [4]. Business Transformation - Biyuan is implementing a profit-centered business improvement strategy, transitioning its offline OTC business through joint ventures, which has led to improved operational quality [3]. - The company has made significant progress in channel development, covering nearly 290,000 OTC pharmacies and medical third terminals across 31 provinces and cities in China [3]. Future Development Strategy - The company plans to leverage the "Weight Management Year" initiative promoted by the National Health Commission, focusing on the core health tea business while deepening reforms and optimizing mechanisms [6]. - Biyuan aims to enhance its brand building and youth-oriented marketing strategies through diversified media channels, targeting younger consumer demographics [4][6]. - Financial health indicators show improvement, with the current ratio rising from 1.58 in 2021 to 2.96 in 2024, and the debt-to-asset ratio decreasing from 35.73% to 15.22% [6].

Core Viewpoint - The company reported a revenue of RMB 259 million for the six months ending June 30, 2025, reflecting a year-on-year increase of 1.82% and a net profit of RMB 12.402 million, which is a significant year-on-year increase of 58.74% [1] Financial Performance - Revenue for the period was RMB 259 million, up 1.82% year-on-year [1] - Net profit reached RMB 12.402 million, marking a 58.74% increase compared to the previous year [1] - Basic earnings per share were reported at 10.14 cents [1] - The company proposed an interim dividend of HKD 0.15 per share [1] Revenue Drivers - The increase in revenue was primarily attributed to strong performance in online e-commerce channels, which partially offset the temporary pressure faced by traditional offline channels [1]

[Financial Summary and Interim Dividend](index=1&type=section&id=Financial%20Summary%20and%20Interim%20Dividend) [Summary of Operating Results](index=1&type=section&id=Summary%20of%20Operating%20Results) The Group achieved steady growth in the first half of 2025, with revenue slightly increasing by **1.8%** to **RMB 259 million**, and gross profit margin modestly rising to **68.6%**, while total comprehensive income increased by **45.9%** to **RMB 12.4 million** due to effective operating expense control, with basic earnings per share rising to **RMB 10.14 cents** Key Financial Indicators for H1 2025 | Indicator | H1 2025 | H1 2024 | YoY Change | | :--- | :--- | :--- | :--- | | Revenue | RMB 258.9 million | RMB 254.3 million | +1.8% | | Gross Profit | RMB 177.6 million | RMB 173.4 million | +2.4% | | Gross Profit Margin | 68.6% | 68.2% | +0.4pp | | Operating Expenses | RMB 164.6 million | RMB 169.3 million | -2.8% | | Total Comprehensive Income | RMB 12.4 million | RMB 8.5 million | +45.9% | | Basic and Diluted Earnings Per Share | RMB 10.14 cents | RMB 6.39 cents | +58.7% | [Interim Dividend](index=2&type=section&id=Interim%20Dividend) The Board proposes an interim dividend of **HKD 0.15** per share for the six months ended June 30, 2025, totaling approximately **HKD 18.3 million**, subject to shareholder approval at a special general meeting - The Board proposes an interim dividend of **HKD 0.15** per share, totaling **HKD 18,339,837.75**, subject to shareholder approval[5](index=5&type=chunk) [Interim Condensed Consolidated Financial Statements](index=3&type=section&id=Interim%20Condensed%20Consolidated%20Financial%20Statements) [Interim Condensed Consolidated Statement of Comprehensive Income](index=3&type=section&id=Interim%20Condensed%20Consolidated%20Statement%20of%20Comprehensive%20Income) For the six months ended June 30, 2025, the Group recorded revenue of **RMB 259 million**, a **1.8%** year-on-year increase, achieving a profit for the period of **RMB 12.402 million**, up **58.7%** from **RMB 7.813 million** in the prior period, despite increased sales and marketing expenses partially offset by reduced administrative and R&D costs Interim Condensed Consolidated Statement of Comprehensive Income | Item | H1 2025 (RMB in thousands) | H1 2024 (RMB in thousands) | | :--- | :--- | :--- | | Revenue | 258,913 | 254,286 | | Gross Profit | 177,551 | 173,435 | | Operating Profit | 15,682 | 11,655 | | Profit Before Income Tax | 20,544 | 13,125 | | **Profit for the Period** | **12,402** | **7,813** | | **Total Comprehensive Income for the Period** | **12,402** | **8,465** | [Interim Condensed Consolidated Statement of Financial Position](index=5&type=section&id=Interim%20Condensed%20Consolidated%20Statement%20of%20Financial%20Position) As of June 30, 2025, the Group's total assets were **RMB 592 million**, a **5.6%** increase from the end of 2024, with total liabilities at **RMB 104 million**, and the debt-to-asset ratio rising from **15.2%** to **17.6%**, while total equity increased to **RMB 488 million** Summary of Interim Condensed Consolidated Statement of Financial Position | Item | June 30, 2025 (RMB in thousands) | December 31, 2024 (RMB in thousands) | | :--- | :--- | :--- | | **Total Non-current Assets** | 312,394 | 325,331 | | **Total Current Assets** | 279,872 | 235,362 | | **Total Assets** | **592,266** | **560,693** | | **Total Equity** | 487,778 | 475,376 | | **Total Liabilities** | 104,488 | 85,317 | | **Total Equity and Liabilities** | **592,266** | **560,693** | [Notes to the Financial Statements](index=7&type=section&id=Notes%20to%20the%20Financial%20Statements) The notes detail the company's basic information, accounting policies, segment information, tax status, and financial data composition, including its primary business of producing and selling functional health teas and weight-loss drugs, segmenting operations into tea products and weight-loss and other pharmaceuticals, and disclosing key customer, tax rate, EPS calculation, and dividend details - The Group's principal activities are the manufacturing and sale of functional health tea products and the sale of weight-loss and other pharmaceutical products[11](index=11&type=chunk) Segment Results for H1 2025 | Segment | Revenue (RMB in thousands) | Segment Results (RMB in thousands) | | :--- | :--- | :--- | | Tea Products Segment | 159,668 | 46,470 | | Weight-Loss and Other Pharmaceutical Products Segment | 99,245 | 1,443 | | **Total** | **258,913** | **47,913** | - In H1 2025, revenue from Customer B and Customer C (both e-commerce platforms) each accounted for over **10%** of the Group's total revenue, at **RMB 30.28 million** and **RMB 30.01 million** respectively[22](index=22&type=chunk) - Basic and diluted earnings per share for H1 2025 were **RMB 10.14 cents**, higher than **RMB 6.39 cents** in the same period last year[31](index=31&type=chunk) [Management Discussion and Analysis](index=17&type=section&id=Management%20Discussion%20and%20Analysis) [Performance Review](index=17&type=section&id=Performance%20Review) In the first half of 2025, the Group maintained a profit-centric, stable operating strategy, achieving smooth transition in offline OTC business and maturing online agency operation models through optimized channel management, significantly enhancing overall operational quality, and making progress in marketing, channel expansion, international business, and R&D innovation, laying a foundation for H2 development [Channel Strategy and Operations](index=18&type=section&id=Channel%20Strategy%20and%20Operations) The Group solidified its market position in offline channels by deepening cooperation with chain pharmacies, multi-platform promotion, and maintaining price systems, while significantly boosting online performance through refined agency operations, platform differentiation, price optimization, AI digital human live streaming, and new media marketing like Xiaohongshu, particularly focusing on core best-selling products on Douyin and leveraging digital marketing systems for efficiency - Offline channels ensured market share and sales scale through deepened cooperation with chain pharmacies, multi-platform promotion, and price control[41](index=41&type=chunk)[42](index=42&type=chunk)[43](index=43&type=chunk) - E-commerce agency operation models were refined, improving operating results across platforms through differentiated strategies, targeted price optimization initiatives, and content operation innovations, such as AI digital human live streaming[44](index=44&type=chunk)[45](index=45&type=chunk)[46](index=46&type=chunk)[48](index=48&type=chunk) - The Xiaohongshu platform was relaunched and strategically focused, driving brand awareness and sales growth through a 'three-dimensional content seeding model' and content loop[49](index=49&type=chunk) - On new business platforms like Douyin, the focus was on core best-selling products in the weight management category, applying AI technology (e.g., 'Kouzi workflow') to enhance content production efficiency and compliance, saving **40%** in labor costs[50](index=50&type=chunk)[52](index=52&type=chunk) [International Business and R&D](index=22&type=section&id=International%20Business%20and%20R%26D) International business made substantial progress with trial orders from Southeast Asian e-commerce platforms and an OEM agreement with a Vietnamese company, alongside packaging upgrades and compliance modifications for US market products; R&D expanded health efficacy research for core products through industry-academia collaboration, actively maintained health food approvals, and strengthened intellectual property by applying for **6** new patents in H1 - International business focused on the Southeast Asian market, securing trial orders with local e-commerce platforms and signing an OEM agreement with a Vietnamese company, while also completing product upgrades for the US market[53](index=53&type=chunk)[54](index=54&type=chunk)[55](index=55&type=chunk) - Through collaboration with Beijing Technology and Business University, industry-academia integration was promoted, with research indicating significant efficacy of Changrun Tea and Changjing Tea in uric acid reduction and liver damage protection, leading to **2** invention patent applications[56](index=56&type=chunk) - In H1, **3** invention patents and **3** utility model patents were applied for, and **1** invention patent was granted, deepening the intellectual property layout[58](index=58&type=chunk) [Business Outlook](index=25&type=section&id=Business%20Outlook) In the second half of 2025, the Group will leverage the 'Weight Management Year' initiative to deepen reforms, integrate online and offline sales advantages, and focus on the 'weight management' and 'bowel regularity and gastrointestinal health' sectors, continuing to promote brand rejuvenation, increase investment in new media and new retail, and continuously develop new products to meet market demand - In the second half, the focus will be on the two core areas of 'weight management' and 'gastrointestinal health,' deepening reforms, integrating online and offline channels, and leveraging new media and new retail to enhance competitiveness[60](index=60&type=chunk) [Financial Review](index=26&type=section&id=Financial%20Review) This financial review details the Group's H1 financial performance, with revenue slightly up **1.8%** driven by strong online channel growth, a modest increase in gross profit margin, higher sales and marketing expenses due to increased e-commerce platform fees, but significantly lower administrative and R&D costs, resulting in healthy operating cash flow, a stable financial position, and a low debt-to-asset ratio [Revenue Analysis](index=26&type=section&id=Revenue%20Analysis) Total revenue for H1 2025 was **RMB 259 million**, a **1.8%** year-on-year increase, primarily driven by weight-loss pharmaceuticals (**+15.0%**) and online channel products 'Orlistat' and 'Xianxian Tea' (growing **41.6%** and **53.5%** respectively), offsetting declines in the Four Teas series (**-4.7%**) and offline channels H1 2025 Revenue Composition (by Product) | Product Category | Revenue (RMB in thousands) | % of Total Revenue | YoY Change | | :--- | :--- | :--- | :--- | | Bishengyuan Changrun Tea | 30,352 | 11.7% | -35.2% | | Bishengyuan Changjing Tea | 50,290 | 19.4% | -7.5% | | Bishengyuan Xianxian Tea | 45,732 | 17.7% | +47.5% | | Bishengyuan Qingyuan Tea | 2,753 | 1.1% | -15.8% | | **Weight-Loss Pharmaceuticals** | **94,368** | **36.4%** | **+15.0%** | | Other Health Foods | 30,541 | 11.8% | -5.0% | | Other Pharmaceuticals | 4,877 | 1.9% | +6.5% | | **Total** | **258,913** | **100.0%** | **+1.8%** | - Online channel products 'Bishengyuan Orlistat' and 'Bishengyuan Xianxian Tea' achieved significant year-on-year sales growth of **41.6%** and **53.5%** respectively[62](index=62&type=chunk) [Cost, Gross Profit, and Expense Analysis](index=27&type=section&id=Cost%2C%20Gross%20Profit%2C%20and%20Expense%20Analysis) Gross profit margin for H1 was **68.6%**, a slight increase of **0.4** percentage points year-on-year; sales and marketing expenses rose **13.3%** to **RMB 125 million**, primarily due to increased e-commerce platform service and traffic acquisition fees, while administrative and R&D costs significantly decreased by **19.6%** and **68.4%** respectively, effectively controlling overall expenses - Gross profit margin slightly increased from **68.2%** to **68.6%**, primarily due to changes in product mix and higher gross profit margins for certain products[63](index=63&type=chunk) - Sales and marketing expenses increased by **13.3%** year-on-year, mainly due to higher e-commerce platform agency operation service fees and platform traffic acquisition costs[64](index=64&type=chunk)[65](index=65&type=chunk) - Administrative expenses decreased by **19.6%** year-on-year, primarily due to a reduction in non-recurring expenditures[66](index=66&type=chunk) - Research and development costs significantly decreased by **68.4%** year-on-year to **RMB 5.0 million**, mainly due to reduced investment in outsourced R&D activities[67](index=67&type=chunk) [Liquidity, Capital Resources, and Investments](index=29&type=section&id=Liquidity%2C%20Capital%20Resources%2C%20and%20Investments) The Group's working capital primarily originates from operating activities, with net cash inflow from operating activities significantly increasing to **RMB 31.8 million** in H1; period-end cash and cash equivalents rose to **RMB 165 million**, with no bank borrowings and a debt-to-asset ratio of **17.6%**, while financial assets measured at fair value were approximately **RMB 78.3 million**, mainly equity investments in various funds and companies Summary of Net Cash Flows (For the Six Months Ended June 30) | Item | 2025 (RMB in thousands) | 2024 (RMB in thousands) | | :--- | :--- | :--- | | Net Cash Inflow from Operating Activities | 31,801 | 12,354 | | Net Cash Inflow from Investing Activities | 389 | 5,574 | | Net Cash Outflow from Financing Activities | (1,803) | (2,414) | | **Cash and Cash Equivalents at End of Period** | **164,542** | **184,518** | - As of June 30, 2025, the Group had no bank borrowings, and its debt-to-asset ratio was **17.6%**[79](index=79&type=chunk)[87](index=87&type=chunk) - The Group held financial assets measured at fair value through profit or loss of **RMB 78.3 million**, and through the consolidated 'Fund No. 6,' held loans receivable of approximately **RMB 69.8 million** and restricted bank deposits of approximately **RMB 13.5 million**[73](index=73&type=chunk)[75](index=75&type=chunk) [Other Information](index=34&type=section&id=Other%20Information) [Compliance, Human Resources, and Corporate Governance](index=34&type=section&id=Compliance%2C%20Human%20Resources%2C%20and%20Corporate%20Governance) The Group strictly adheres to all laws and regulations, with no significant compliance incidents, maintaining good relationships with employees, suppliers, and customers; as of period-end, the Group had **129** employees, and in corporate governance, it complies with the Corporate Governance Code, having completed the separation of CEO and Chairman functions in June 2025, with the Audit Committee reviewing the current financial information - The Group's operations comply with relevant laws and regulations, with no significant non-compliance issues identified, and maintains good stakeholder relationships[90](index=90&type=chunk)[91](index=91&type=chunk) - As of June 30, 2025, the Group had **129** employees, with staff costs of **RMB 22.5 million** in H1[92](index=92&type=chunk) - In June 2025, Mr. Zhao Yihong was re-designated from Chief Executive Officer to Chief Strategy Officer, and Mr. Feng Bing was appointed Chief Executive Officer, with the company subsequently complying with the Corporate Governance Code's requirement for separation of Chairman and CEO functions[94](index=94&type=chunk) [Dividends, Share Repurchases, and Other Disclosures](index=36&type=section&id=Dividends%2C%20Share%20Repurchases%2C%20and%20Other%20Disclosures) The Board proposes an interim dividend of **HKD 0.15** per share and announced the specific timetable for dividend payment; during the reporting period, neither the company nor its subsidiaries purchased, sold, or redeemed any listed securities, and the company is discussing arrangements for full redemption of its participating shares in 'Fund No. 6' with the fund manager - During the first half, neither the company nor its subsidiaries purchased, sold, or redeemed any of the company's listed securities[96](index=96&type=chunk) - The company is discussing arrangements and a timetable for the full cash redemption of its participating shares in 'Zhongzhou Longteng Global Opportunity Fund No. 6' with the fund manager[99](index=99&type=chunk) - Other than the disclosed dividend proposal, no other post-balance sheet events with significant impact on the Group have occurred from the end of the period to the date of this announcement[100](index=100&type=chunk)

Core Viewpoint - The company Biyuan (00926.HK) announced a mid-term dividend distribution of HKD 0.15 per share, scheduled for September 12, 2025 [1] Company Summary - Biyuan will distribute a mid-term dividend of HKD 0.15 per share [1]